Theravance Biopharma (TBPH) EBITDA Margin (2013 - 2026)
Theravance Biopharma (TBPH) reported EBITDA Margin of 53.58% for Q1 2026, up 3471.0% year-over-year from 1.5% in Q1 2025, and down 166.93% on a QoQ basis from 80.05% in Q4 2025.
Theravance Biopharma (TBPH) has 14 years of EBITDA Margin data on file, last reported at 53.58% in Q1 2026.
- Quarterly EBITDA Margin rose 3471.0% year-over-year to 53.58% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.64% (up 15720.0% YoY) and the FY2025 annual result came in at 430.83%, up 50375.0% from the prior year.
- EBITDA Margin fell to 53.58% in Q1 2026 per TBPH's latest filing, from 80.05% in the prior quarter.
- Across five years, EBITDA Margin topped out at 7361.3% in Q3 2022 and bottomed at 1038.96% in Q1 2022.
- The 5-year median for EBITDA Margin is 74.28% (2022), against an average of 326.77%.
- The widest annual swing landed in 2022, when EBITDA Margin jumped 762886 bps; it then slumped 741794 bps in 2023.
- Tracing TBPH's EBITDA Margin over 5 years: stood at 119.0% in 2022, then jumped by 70 bps to 35.53% in 2023, then tumbled by 38 bps to 49.06% in 2024, then soared by 263 bps to 80.05% in 2025, then slumped by 167 bps to 53.58% in 2026.
- Per Business Quant, the three latest TBPH EBITDA Margin figures stand at 53.58% (Q1 2026), 80.05% (Q4 2025), and 18.29% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Theravance Biopharma | 823.54 Mn | 428.87 Mn | - | -53.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.58% |
| Dec 31, 2025 | 80.05% |
| Sep 30, 2025 | 18.29% |
| Jun 30, 2025 | 209.30% |
| Mar 31, 2025 | -88.29% |
| Dec 31, 2024 | -49.06% |
| Sep 30, 2024 | -74.85% |
| Jun 30, 2024 | -115.81% |
| Mar 31, 2024 | -80.26% |
| Dec 31, 2023 | -35.53% |
| Sep 30, 2023 | -56.64% |
| Jun 30, 2023 | -116.24% |
| Mar 31, 2023 | -211.40% |
| Dec 31, 2022 | -119.00% |
| Sep 30, 2022 | 7,361.30% |
| Jun 30, 2022 | -74.28% |
| Mar 31, 2022 | -1,038.96% |
| Dec 31, 2021 | -375.80% |
| Sep 30, 2021 | -267.56% |
| Jun 30, 2021 | -405.87% |
| Mar 31, 2021 | -559.09% |
| Dec 31, 2020 | -408.38% |
| Sep 30, 2020 | -404.23% |
| Jun 30, 2020 | -420.57% |
| Mar 31, 2020 | -5,512.40% |
| Dec 31, 2019 | -29.41% |
| Sep 30, 2019 | -470.48% |
| Jun 30, 2019 | -73.47% |
| Mar 31, 2019 | -1,357.25% |
| Dec 31, 2018 | -397.92% |
| Sep 30, 2018 | -461.43% |
| Jun 30, 2018 | -172.47% |
| Mar 31, 2018 | -783.83% |
| Dec 31, 2017 | -1,753.62% |
| Sep 30, 2017 | -1,565.40% |
| Jun 30, 2017 | -1,888.37% |
| Mar 31, 2017 | -2,116.55% |
| Dec 31, 2016 | -1,016.06% |
| Sep 30, 2016 | -178.79% |
| Jun 30, 2016 | -862.18% |
| Mar 31, 2016 | -227.89% |
| Dec 31, 2015 | -1,432.67% |
| Sep 30, 2015 | -442.09% |
| Jun 30, 2015 | -667.37% |
| Mar 31, 2015 | -207.64% |
| Dec 31, 2014 | -4,588.49% |
| Sep 30, 2014 | -861.62% |
| Jun 30, 2014 | -1,906.72% |
| Mar 31, 2014 | -6,351.11% |
| Dec 31, 2013 | -25,188.57% |
| Sep 30, 2013 | -171,158.33% |
| Jun 30, 2013 | -779,040.00% |
| Mar 31, 2013 | -146,245.45% |